All In Biotech

Free tool

FAERS Monitor: Simbrinza

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 204251 or its brand name (Simbrinza, Brimonidine Tartrate, Brinzolamide). Reports on generic versions are filed under their own applications.

Reports

4,182

Serious

1,782

43% of reports

Hospitalization

442

Death reported

150

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • treatment failure382
  • ocular hyperaemia366
  • drug ineffective354
  • eye irritation353
  • vision blurred259
  • eye pain237
  • dizziness204
  • hypersensitivity198
  • intraocular pressure increased186
  • visual impairment180
  • fatigue174
  • glaucoma157
  • eye pruritus126
  • headache120
  • drug hypersensitivity117

Reports by year received

View as table
YearReports
20121
201315
201451
2015156
2016367
2017507
2018547
2019487
2020753
2021333
2022190
2023193
2024218
2025213
2026151

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,977 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
intraocular pressure increasedSignal18674.364.513,184
glaucomaSignal15741.335.46,095
ocular hyperaemiaSignal36639.135.413,469
eye irritationSignal35331.028.110,194
treatment failureSignal38223.321.28,123
eye painSignal23721.218.74,537
eye pruritusSignal12618.915.92,117
vision blurredSignal2599.58.41,971
visual impairmentSignal1807.36.3979
hypersensitivitySignal1985.44.7705
drug hypersensitivitySignal1173.02.5160
dizzinessSignal2042.11.8112
drug ineffective3541.41.234
fatigue1741.11.02
headache1201.00.80

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.